1EKTA Stock Overview

A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details

1EKTA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 50.8% below our estimate of its fair value

Earnings are forecast to grow 19.11% per year

Risk Analysis

Shares are highly illiquid

Dividend of 4.2% is not well covered by free cash flows

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Elekta AB (publ) Competitors

DiaSorin

BIT:DIA

€5.1b

EL.En

BIT:ELN

€758.3m

I.M.D. International Medical Devices

BIT:IMD

€23.9m

Amplifon

BIT:AMP

€4.5b

Price History & Performance

Summary of share price highs, lows and changes for Elekta
Historical stock prices
Current Share Price	SEK 5.28
52 Week High	SEK 0
52 Week Low	SEK 0
Beta	1.13
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-0.47%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1EKTA	IT Medical Equipment	IT Market
7D	-0.5%	-3.2%	0.5%
1Y	n/a	3.1%	12.6%

Return vs Industry: Insufficient data to determine how 1EKTA performed against the Italian Medical Equipment industry.

Return vs Market: Insufficient data to determine how 1EKTA performed against the Italian Market.

Price Volatility

Is 1EKTA's price volatile compared to industry and market?
1EKTA volatility
1EKTA Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.5%
10% most volatile stocks in IT Market	8.0%
10% least volatile stocks in IT Market	2.7%

Stable Share Price: 1EKTA's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1EKTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1972	4,541	Jonas Bolander	elekta.com

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.

Elekta AB (publ) Fundamentals Summary

How do Elekta's earnings and revenue compare to its market cap?
1EKTA fundamental statistics
Market cap	€1.98b
Earnings (TTM)	€94.17m
Revenue (TTM)	€1.62b

21.1x

P/E Ratio

1.2x

P/S Ratio

Is 1EKTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1EKTA income statement (TTM)
Revenue	SEK 17.88b
Cost of Revenue	SEK 11.31b
Gross Profit	SEK 6.57b
Other Expenses	SEK 5.53b
Earnings	SEK 1.04b

Last Reported Earnings

Jan 31, 2025

Next Earnings Date

May 28, 2025

Earnings per share (EPS)	2.72
Gross Margin	36.75%
Net Profit Margin	5.80%
Debt/Equity Ratio	70.4%

How did 1EKTA perform over the long term?

See historical performance and comparison

Dividends

4.2%

Current Dividend Yield

88%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/16 07:41
End of Day Share Price	2025/03/14 00:00
Earnings	2025/01/31
Annual Earnings	2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Elekta AB (publ) is covered by 40 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Sumit Sayal	AlphaValue
Hassan Al-Wakeel	Barclays